Last reviewed 2026-06-10 · How we verify

Congenital myotonia, autosomal dominant form — Treatment Landscape & Competitive Intelligence

Congenital myotonia, autosomal dominant form (disease) competitive landscape: 0 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Congenital myotonia, autosomal dominant form, deduplicated by molecule. See the full disease page for line-of-therapy detail.

No marketed treatments tracked for this disease yet.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Congenital myotonia, autosomal dominant form:

• Congenital myotonia, autosomal dominant form treatment updates — RSS
• Congenital myotonia, autosomal dominant form treatment updates — Atom
• Congenital myotonia, autosomal dominant form treatment updates — JSON

Cite this brief

Drug Landscape (2026). Congenital myotonia, autosomal dominant form — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/congenital-myotonia-autosomal-dominant-form. Accessed 2026-06-10.

Related

• Congenital myotonia, autosomal dominant form full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing